Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
The supply agreement is designed to support the evaluation of Immuneerings lead candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase II trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy
DOWNLOADABLE RESOURCE Get your copy of our GLP-1s: 2024 Trends in Drug Benefit Design Report Findings to help you make the best decisions in the current benefits landscape
To better understand how GLP-1 medications are used in clinical practice for medical weight management, learn more about Bay Medical's GLP-1 medication programmes and doctor-led treatment approach
iLISI was calculated using the first 20 principal components before Harmony correction and the first 20 Harmony-corrected dimensions after integration, with dataset identity used as the batch label
Take an alcohol prep pad and vigorously scrub the rubber stopper on top of each vial for several seconds
US$ 21.05
US$ 22.20
US$ 23.94
US$ 25.93
US$ 27.35
US$ 27.20
US$ 22.51
US$ 23.06
US$ 23.47
US$ 21.87
